ProVise Management Group LLC Has $8.58 Million Stock Holdings in Sanofi (NASDAQ:SNY)

ProVise Management Group LLC lifted its position in Sanofi (NASDAQ:SNY) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,728 shares of the company’s stock after acquiring an additional 5,509 shares during the quarter. ProVise Management Group LLC’s holdings in Sanofi were worth $8,575,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in SNY. Boston Partners grew its position in Sanofi by 0.3% during the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after buying an additional 33,657 shares during the period. Bank of New York Mellon Corp grew its position in Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares during the period. Mondrian Investment Partners LTD boosted its position in Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the period. Envestnet Asset Management Inc. boosted its position in Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares during the period. Finally, Federated Hermes Inc. boosted its position in Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after purchasing an additional 673,172 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 1.0 %

SNY stock opened at $57.47 on Thursday. The company has a market capitalization of $145.56 billion, a PE ratio of 28.88, a price-to-earnings-growth ratio of 1.60 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $58.97. The company’s 50 day moving average price is $54.08 and its two-hundred day moving average price is $50.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter last year, the business earned $0.95 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. As a group, analysts predict that Sanofi will post 4.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 11th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday. Finally, Argus increased their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.